Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,639 public trials 556 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Icahn School of Medicine at Mt. Sinai New York, United States
View all 38 locations
View Trial Details
Recruiting

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations
  • Monash Medical Centre Clayton, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
  • Peter MacCallum Cancer Centre Melbourne, Australia
  • Calvary Mater Newcastle Hospital Waratah, Australia
View all 16 locations
View Trial Details
Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • Memorial Healthcare System Hollywood, Florida, United States
View all 78 locations
View Trial Details
Recruiting

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cytokine Release Syndrome, +19 more
Locations
  • Berenson Cancer Center Los Angeles, California, United States
  • Mary Bird Perkins Cancer Center Baton Rouge, Louisiana, United States
  • Northwest Medical Specialties, PLLC Tacoma, Washington, United States
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders Bethesda, Maryland, United States
View Trial Details
Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 20 locations
View Trial Details
Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Emory University - Winship Cancer Institute Atlanta, Georgia, United States
  • Dana Farber / Harvard Cancer Center Boston, Massachusetts, United States
  • Barbara Ann Karmanos Cancer Institute - Detroit Detroit, Michigan, United States
  • Mayo Clinic Phoenix, Mayo Clinic Building Phoenix, Arizona, United States
View all 19 locations
View Trial Details
Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

NCT07073547

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Tampa, Florida, United States
View all 13 locations
View Trial Details
Recruiting

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

NCT06052826

Conditions
B-Cell Non-Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology Winston-Salem, North Carolina, United States
  • Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology Columbus, Ohio, United States
View Trial Details
Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UAMS Little Rock, Arkansas, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 150 locations
View Trial Details

Related conditions